Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 6;11:4573–4582. doi: 10.2147/OTT.S170722

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Reck et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Tumor size over time, measured by SLD of target lesions, in patients with adenocarcinoma.

Notes: Trajectories are based on the estimated fixed effects of the mixed model. (A) All patients with adenocarcinoma. (B) Patients with adenocarcinoma who progressed within 9 months after start of first-line therapy (TSFLT <9). (C) Patients with adenocarcinoma with PD-FLT.

Abbreviations: PD-FLT, progressive disease as the best response to first-line therapy; SLD, sum of longest diameter; t, time from randomization; TSFLT <9, time from start of first-line therapy <9 months.